SLC5A2 and diabetic kidney disease: Despite recent advances in the therapeutic landscape, including the addition of sodium-glucose cotransporter-2 (SGLT2) inhibitors and nonsteroidal mineralocorticoid receptor antagonists to the armamentarium, patients with DKD continue to have a substantial residual risk of kidney and cardiovascular morbidity and mortality (4).